1. Home
  2. BNGO vs APVO Comparison

BNGO vs APVO Comparison

Compare BNGO & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bionano Genomics Inc.

BNGO

Bionano Genomics Inc.

HOLD

Current Price

$1.53

Market Cap

24.3M

Sector

Industrials

ML Signal

HOLD

Logo Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc.

HOLD

Current Price

$1.02

Market Cap

21.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNGO
APVO
Founded
2003
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.3M
21.7M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
BNGO
APVO
Price
$1.53
$1.02
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$6.33
N/A
AVG Volume (30 Days)
203.9K
1.0M
Earning Date
11-13-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$28,720,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$24.56
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.45
$1.00
52 Week High
$22.80
$109.80

Technical Indicators

Market Signals
Indicator
BNGO
APVO
Relative Strength Index (RSI) 39.99 35.80
Support Level $1.61 $1.00
Resistance Level $1.63 $1.11
Average True Range (ATR) 0.07 0.09
MACD -0.00 -0.01
Stochastic Oscillator 4.06 3.66

Price Performance

Historical Comparison
BNGO
APVO

About BNGO Bionano Genomics Inc.

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: